An interventional study of Life Skills and Resilience Program in Autism Spectrum Disorder, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 431st largest by enrollment of the 658 interventional ones that give a count, is one of 60 that started in 2019, is one of 456 with no phase, and was the 333rd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Northeastern University · Sites in United States
Ages 33 mo–71 mo
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 18 Years to 26 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 60 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 523 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 7 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
69 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 69 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effects of a 12-week life-skills resilience curriculum for young adults with autism. The project utilizes a cohort single arm design.
As young adults with autism spectrum disorder (YAASD) transition out of the academic supports provided by school, these young adults experience a degradation of social skills over time. This has led to poor academic, educational and health outcomes. YAASD require continuous and ongoing skill development in order to maximize their potential; however, there are few services available to adults with autism to develop and maintain their skills. While interventions exist in early childhood, mid-childhood and adolescence, few programs have been focused on the young adult with autism. Resilience in Action (RiA), is a research study, performed and delivered in the community setting, which seeks to develop supports to address the 'adult world' needs of young adults with autism exiting out of secondary education.
The investigators propose to develop this program through three specific aims. In the first aim, the investigators propose in-depth interviews with adults with autism and/or their families and service providers to better understand barriers and facilitators to "adult living" after graduating out of the school system. In the second aim, the investigators will use the information gained from Aim 1 to develop a 12-week curriculum integrating a resilience framework and methodologies into a community adult life skills program for persons with disabilities. A trained transition curriculum expert who had developed transition curriculum for youth with autism spectrum disorder in our local school district will assist in this "adult" curriculum to fill gaps that exist in the school district curriculum. As part of the infrastructure and support for this pilot, the investigators will generate a protocol for the participant's existing case manager to help support youth and families after the curriculum is completed. The third aim is to then pilot test RiA on 30 young adults with autism who have recently graduated from the secondary education system. Through an iterative program evaluation, the investigators will further hone the intervention and adapt the program to different levels of disability and learning styles. The investigators will measure characteristics of those who were successfully engaged in the program and measure outcomes such as socialization, quality of life, vocational/social activities and self-efficacy. Through this research the investigators will have developed a final protocol for a resiliency course to be tested in a larger clinical trial to see how this type of curriculum can improve longer term social and health outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
Behavioral: Life Skills and Resilience Program
The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
Resilience Scale
Resilience Scale (RS) developed by Wagnild and Young (1990) * Personal competence and acceptance of self and life, which measures the construct of resilience. * Adapted for 2nd and 5th grade reading level * Possible scores range from 25 to 175 with higher scores reflecting higher resilience
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline measure)
McMaster Family Assessment Device (FAD), General Functioning Subscale
McMaster Family Assessment Device (FAD), General Functioning Subscale * The General Functioning Subscale ranges from 1 to 4 with higher scores indicating worse levels of family functioning. * A score of 2.00 in an individual item or above indicates problematic family functioning. * 12 questions score range 12-48
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline)
PROMIS: Self Efficacy Scale
PROMIS® Self-Efficacy score A person's belief in his/her capacity to manage functioning and have control over meaningful events. The higher the score, the higher the capacity to manage functioning and control over meaningful events. * Raw scores reported (ranging from 10 to 50) * A higher PROMIS represents greater satisfaction with self-efficacy
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline)
Pediatric Quality of Life
Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales * Validated quality of life measure that has been developed across different developmental ages and adults * Scale ranges from 0 to 100 and higher scores indicate better Health-Related Quality of Life * Four sub-scales include Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning * Total Scale Score is the mean computed as the sum of all the items over the number of items answered on all the Scales
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline)
Satisfaction With Social Roles (v2.0)
PROMIS Satisfaction with Social Roles (v2.0) * Measures satisfaction with performing one's usual social roles (e.g., "I am satisfied with my ability to participate in family activities") * Raw scores (ranging from 6 to 40) are converted to T-scores with a mean of 50 and standard deviation of 10 * A higher PROMIS T-score represents greater satisfaction with social roles and activities.
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline)
Employment/Volunteer Status
Percentage of study participants employed or volunteering. Please note that work was measured during the COVID-19 pandemic, which started right after the study began.
Time frame: Assessed at baseline and 3-6 months post completion (up to 9 months post baseline)
Persons with autism over age 19-26.
| Milestone | Resilience Training |
|---|---|
| Started | 30 |
| Completed | 30 |
| Not completed | 0 |
Resilience Scale (RS) developed by Wagnild and Young (1990) * Personal competence and acceptance of self and life, which measures the construct of resilience. * Adapted for 2nd and 5th grade reading level * Possible scores range from 25 to 175 with higher scores reflecting higher resilience
| units on a scale | Baseline Measure | Post Completion |
|---|---|---|
| Resilience Scale | 111.5556 ± 22.5 | 114.28 ± 31.12678 |
McMaster Family Assessment Device (FAD), General Functioning Subscale * The General Functioning Subscale ranges from 1 to 4 with higher scores indicating worse levels of family functioning. * A score of 2.00 in an individual item or above indicates problematic family functioning. * 12 questions score range 12-48
| score on scale | Baseline Measure | Post-intervention |
|---|---|---|
| McMaster Family Assessment Device (FAD), General Functioning Subscale | 23.93 ± 7.07 | 23.88 ± 4.90 |
PROMIS® Self-Efficacy score A person's belief in his/her capacity to manage functioning and have control over meaningful events. The higher the score, the higher the capacity to manage functioning and control over meaningful events. * Raw scores reported (ranging from 10 to 50) * A higher PROMIS represents greater satisfaction with self-efficacy
| units on a scale | Baseline Measure | Post Completion |
|---|---|---|
| PROMIS: Self Efficacy Scale | 30.65 ± 9.08 | 31.72 ± 8.96 |
Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales * Validated quality of life measure that has been developed across different developmental ages and adults * Scale ranges from 0 to 100 and higher scores indicate better Health-Related Quality of Life * Four sub-scales include Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning * Total Scale Score is the mean computed as the sum of all the items over the number of items answered on all the Scales
| score on a scale | Baseline Measure | Post Completion |
|---|---|---|
| Pediatric Quality of Life | 69.0 ± 17.72 | 71.50 ± 13.68 |
PROMIS Satisfaction with Social Roles (v2.0) * Measures satisfaction with performing one's usual social roles (e.g., "I am satisfied with my ability to participate in family activities") * Raw scores (ranging from 6 to 40) are converted to T-scores with a mean of 50 and standard deviation of 10 * A higher PROMIS T-score represents greater satisfaction with social roles and activities.
| units on a scale | Baseline Measure | Post Completion |
|---|---|---|
| Satisfaction With Social Roles (v2.0) | 48.12 ± 14.63 | 47.88 ± 13.62 |
Percentage of study participants employed or volunteering. Please note that work was measured during the COVID-19 pandemic, which started right after the study began.
| Participants | Baseline Measure | Post Completion |
|---|---|---|
| Not working | 17 | 21 |
| Working | 13 | 7 |
Collected over From enrollment to the end of course, which was approximately 20 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Resilience Training | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
This is a study of young adults with autism (age 19-26) who are participating in a life skills course to improve reslience.
| Age, Categorical(Participants) | Resilience Training |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 30 |
| >=65 years | 0 |
| Age, Continuous(years) | Resilience Training |
|---|---|
| Mean | 23.3 ± 2.2 |
| Sex: Female, Male(Participants) | Resilience Training |
|---|---|
| Female | 3 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Resilience Training |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Resilience Training |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 13 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 12 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Resilience Training |
|---|---|
| United States | 30 |
| ABAS score(units on a scale) | Resilience Training |
|---|---|
| Mean | 70.33 ± 15.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Jul 2021, 30 months.
Results were first posted in Oct 2026, 5 years 2 months after primary completion.
Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 30 months is above that.
Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion May 2021 → Jul 2021 and completion May 2021 → Jul 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →